RCGD423 is primarily used in research settings as a selective agonist for the retinoid X receptor (RXR) gamma subtype. Its main application lies in the study of nuclear receptor signaling pathways, particularly in understanding metabolic regulation, cell differentiation, and potential therapeutic strategies for metabolic and neurodegenerative diseases. Due to its selectivity for RXRγ, it serves as a valuable tool in probing tissue-specific RXR functions, especially in skeletal muscle and the central nervous system. It has also been explored in preclinical studies investigating insulin sensitization and glucose homeostasis, suggesting potential relevance in type 2 diabetes research. However, it remains strictly a research compound with no approved clinical or industrial applications at this time.